^
    BIOMARKER:
    No biomarker
    Associations
    Heatmap
    News
    Twitter
    Trials
    No biomarker
    Endometrial Cancer
    pembrolizumab + lenvatinib
    Sensitive
    :
    A1
    Merck (MSD) Press Release - 1d
    No biomarker
    RCC
    pembrolizumab + lenvatinib
    Sensitive
    :
    B
    Merck (MSD) Press Release - 1d
    No biomarker
    Prostate Cancer
    enzalutamide
    Sensitive
    :
    A1
    Astellas Press Release - 3d
    No biomarker
    Prostate Cancer
    apalutamide
    Sensitive
    :
    A1
    J Clin Oncol - 1wk
    No biomarker
    CLL
    zanubrutinib
    Sensitive
    :
    A1
    BeiGene Press Release - 1wk
    No biomarker
    Small Lymphocytic Lymphoma
    zanubrutinib
    Sensitive
    :
    A1
    BeiGene Press Release - 1wk
    No biomarker
    Urothelial Cancer
    nivolumab
    Sensitive
    :
    A1
    Bristol-Myers Squibb Press Release - 1wk
    No biomarker
    Urothelial Cancer
    pembrolizumab
    Sensitive
    :
    A1
    NICE - 1wk
    No biomarker
    RCC
    Krabeva (bevacizumab biosimilar)
    Sensitive
    :
    A1
    Biocon Press Release - 1wk
    No biomarker
    Cervical Cancer
    Krabeva (bevacizumab biosimilar)
    Sensitive
    :
    A1
    Biocon Press Release - 1wk
    No biomarker
    Ovarian Cancer
    Krabeva (bevacizumab biosimilar)
    Sensitive
    :
    A1
    Biocon Press Release - 1wk
    No biomarker
    GBM
    Krabeva (bevacizumab biosimilar)
    Sensitive
    :
    A1
    Biocon Press Release - 1wk
    No biomarker
    CRC
    Krabeva (bevacizumab biosimilar)
    Sensitive
    :
    A1
    Biocon Press Release - 1wk
    No biomarker
    Breast Cancer
    Krabeva (bevacizumab biosimilar)
    Sensitive
    :
    A1
    Biocon Press Release - 1wk
    No biomarker
    NSCLC
    Krabeva (bevacizumab biosimilar)
    Sensitive
    :
    A1
    Biocon Press Release - 1wk
    No biomarker
    Peritoneal Cancer
    olaparib + bevacizumab
    Sensitive
    :
    A2
    NICE - 1wk
    No biomarker
    Fallopian Tube Cancer
    olaparib + bevacizumab
    Sensitive
    :
    A2
    NICE - 1wk
    No biomarker
    Ovarian Cancer
    olaparib + bevacizumab
    Sensitive
    :
    A2
    NICE - 1wk
    No biomarker
    Malignant Pleural Mesothelioma
    nivolumab + ipilimumab
    Sensitive
    :
    A1
    Bristol-Myers Squibb Press Release - 2wk
    No biomarker
    AML
    azacitidine oral
    Sensitive
    :
    A1
    Bristol-Myers Squibb Press Release - 2wk
    No biomarker
    AML
    venetoclax
    Sensitive
    :
    A1
    Roche Press Release - 2wk
    No biomarker
    Triple Negative Breast Cancer
    sacituzumab govitecan-hziy
    Sensitive
    :
    A1
    N Engl J Med - 2wk
    No biomarker
    Diffuse Large B Cell Lymphoma
    loncastuximab tesirine
    Sensitive
    :
    A1
    FDA - 2wk
    No biomarker
    Multiple Myeloma
    isatuximab-irfc
    Sensitive
    :
    A1
    Sanofi Press Release - 2wk
    No biomarker
    Multiple Myeloma
    ALLO-715
    Sensitive
    :
    B
    Allogene Therapeutics Press Release - 2wk
    No biomarker
    Gastroesophageal Junction Adenocarcinoma
    nivolumab
    Sensitive
    :
    A1
    FDA - 3wk
    No biomarker
    Esophageal Adenocarcinoma
    nivolumab
    Sensitive
    :
    A1
    FDA - 3wk
    No biomarker
    Gastric Cancer
    nivolumab
    Sensitive
    :
    A1
    FDA - 3wk
    No biomarker
    Small Cell Lung Cancer
    durvalumab
    Sensitive
    :
    A1
    ESMO.org - 3wk
    No biomarker
    Small Cell Lung Cancer
    atezolizumab
    Sensitive
    :
    A1
    ESMO.org - 3wk
    No biomarker
    Urothelial Cancer
    sacituzumab govitecan-hziy
    Sensitive
    :
    A1
    FDA - 3wk
    No biomarker
    Small Cell Lung Cancer
    topotecan
    Sensitive
    :
    A1
    ESMO.org - 3wk
    No biomarker
    Small Cell Lung Cancer
    lurbinectedin
    Sensitive
    :
    A1
    ESMO.org - 3wk
    No biomarker
    Multiple Myeloma
    selinexor
    Sensitive
    :
    A1
    NCCN - 3wk
    No biomarker
    NSCLC
    nivolumab
    Sensitive
    :
    A1
    Bristol-Myers Squibb Press Release - 3wk
    No biomarker
    Multiple Myeloma
    idecabtagene vicleucel
    Sensitive
    :
    A1
    NCCN - 3wk
    No biomarker
    Urothelial Cancer
    toripalimab
    Sensitive
    :
    A1
    GlobeNewswire - 3wk
    No biomarker
    Small Cell Lung Cancer
    CAV
    Sensitive
    :
    A2
    ESMO.org - 3wk
    No biomarker
    CML
    bosutinib
    Sensitive
    :
    A2
    Int J Hematol - 3wk
    No biomarker
    Small Cell Lung Cancer
    cisplatin
    Sensitive
    :
    A2
    ESMO.org - 3wk
    No biomarker
    Small Cell Lung Cancer
    carboplatin
    Sensitive
    :
    A2
    ESMO.org - 3wk
    No biomarker
    Small Cell Lung Cancer
    carboplatin + etoposide IV
    Sensitive
    :
    A2
    ESMO.org - 3wk
    No biomarker
    Small Cell Lung Cancer
    cisplatin + etoposide IV
    Sensitive
    :
    A2
    ESMO.org - 3wk
    No biomarker
    Small Cell Lung Cancer
    carboplatin + gemcitabine
    Sensitive
    :
    A2
    ESMO.org - 3wk
    No biomarker
    Small Cell Lung Cancer
    cisplatin + topotecan
    Sensitive
    :
    A2
    ESMO.org - 3wk
    No biomarker
    Small Cell Lung Cancer
    cisplatin + irinotecan
    Sensitive
    :
    A2
    ESMO.org - 3wk
    No biomarker
    Multiple Myeloma
    selinexor + pomalidomide
    Sensitive
    :
    A2
    NCCN - 3wk
    No biomarker
    Multiple Myeloma
    selinexor + daratumumab
    Sensitive
    :
    A2
    NCCN - 3wk
    No biomarker
    Multiple Myeloma
    pomalidomide + elotuzumab
    Sensitive
    :
    A1
    No biomarker
    Diffuse Large B Cell Lymphoma
    lisocabtagene maraleucel
    Sensitive
    :
    A1
    No biomarker
    NSCLC
    ramucirumab
    Sensitive
    :
    A1
    No biomarker
    NSCLC
    durvalumab
    Sensitive
    :
    A1
    No biomarker
    RCC
    nivolumab + cabozantinib tablet
    Sensitive
    :
    A1
    No biomarker
    Follicular Lymphoma
    axicabtagene ciloleucel
    Sensitive
    :
    A1
    No biomarker
    Diffuse Large B Cell Lymphoma
    axicabtagene ciloleucel
    Sensitive
    :
    A1
    No biomarker
    Mediastinal B Cell Lymphoma
    axicabtagene ciloleucel
    Sensitive
    :
    A1
    No biomarker
    Esophageal Squamous Cell Carcinoma
    nivolumab
    Sensitive
    :
    A1
    No biomarker
    Fallopian Tube Cancer
    niraparib
    Sensitive
    :
    A1
    No biomarker
    Ovarian Cancer
    niraparib
    Sensitive
    :
    A1
    No biomarker
    Peritoneal Cancer
    niraparib
    Sensitive
    :
    A1
    No biomarker
    Mantle Cell Lymphoma
    brexucabtagene autoleucel
    Sensitive
    :
    A1
    No biomarker
    NHL
    brentuximab vedotin
    Sensitive
    :
    A1
    No biomarker
    NSCLC
    bevacizumab
    Sensitive
    :
    A1
    No biomarker
    NSCLC
    nivolumab + ipilimumab
    Sensitive
    :
    A1
    No biomarker
    SCCHN
    cisplatin + 5-fluorouracil + docetaxel
    Sensitive
    :
    A1
    No biomarker
    Gastric Adenocarcinoma
    cisplatin + 5-fluorouracil + docetaxel
    Sensitive
    :
    A1
    No biomarker
    Gastroesophageal Junction Adenocarcinoma
    cisplatin + 5-fluorouracil + docetaxel
    Sensitive
    :
    A1
    No biomarker
    NSCLC
    cisplatin + pemetrexed
    Sensitive
    :
    A1
    No biomarker
    NSCLC
    DP
    Sensitive
    :
    A1
    No biomarker
    Breast Cancer
    docetaxel + doxorubicin hydrochloride + cyclophosphamide intravenous
    Sensitive
    :
    A1
    No biomarker
    BCC
    fluorouracil topical
    Sensitive
    :
    A1
    No biomarker
    Lung Non-Squamous Non-Small Cell Cancer
    cisplatin
    Sensitive
    :
    A1
    VERI is free for non-commercial use, no login needed.
    Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
    For commercial access, including additional premium features, please contact us.
    By using VERI, you are agreeing to our
    and
    Privacy Policy
    ACCEPT COOKIES